Free Trial
NASDAQ:DTIL

Precision BioSciences (DTIL) Stock Price, News & Analysis

Precision BioSciences logo
$8.37 -0.01 (-0.12%)
(As of 11/12/2024 ET)

About Precision BioSciences Stock (NASDAQ:DTIL)

Key Stats

Today's Range
$8.20
$8.40
50-Day Range
$8.07
$10.50
52-Week Range
$7.97
$19.43
Volume
200,773 shs
Average Volume
77,763 shs
Market Capitalization
$64.20 million
P/E Ratio
139.52
Dividend Yield
N/A
Price Target
$39.50
Consensus Rating
Buy

Company Overview

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Precision BioSciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
83rd Percentile Overall Score

DTIL MarketRank™: 

Precision BioSciences scored higher than 83% of companies evaluated by MarketBeat, and ranked 198th out of 986 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Precision BioSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Precision BioSciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Precision BioSciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Precision BioSciences are expected to grow in the coming year, from ($1.23) to ($1.05) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Precision BioSciences is 139.52, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 130.87.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Precision BioSciences is 139.52, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 131.66.

  • Price to Book Value per Share Ratio

    Precision BioSciences has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Precision BioSciences' valuation and earnings.
  • Percentage of Shares Shorted

    5.77% of the float of Precision BioSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Precision BioSciences has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Precision BioSciences has recently increased by 0.05%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Precision BioSciences does not currently pay a dividend.

  • Dividend Growth

    Precision BioSciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.77% of the float of Precision BioSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Precision BioSciences has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Precision BioSciences has recently increased by 0.05%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Precision BioSciences has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for Precision BioSciences this week, compared to 2 articles on an average week.
  • Search Interest

    Only 2 people have searched for DTIL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Precision BioSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Precision BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,668.00 in company stock.

  • Percentage Held by Insiders

    Only 4.00% of the stock of Precision BioSciences is held by insiders.

  • Percentage Held by Institutions

    Only 37.99% of the stock of Precision BioSciences is held by institutions.

  • Read more about Precision BioSciences' insider trading history.
Receive DTIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter.

DTIL Stock News Headlines

FY2024 Earnings Estimate for DTIL Issued By HC Wainwright
This thing would have won 534 of the 550 trades placed in the last 11 years
Choosing what your next move will be is one of the most difficult choices investors are faced with today — especially in turbulent markets like these. But what if there was one technique that checked all these boxes? ✅ Allows traders of all stripes to target extra income week after week ✅ Won 534 of 550 trades according to our backtesting on 11-years worth of data ✅ Has maintained a shocking 97.1% through every market condition imaginable ✅ Sets up “Weekly Windfalls” every week so that it’s never trading opposite the broad market direction Well, we’re here to tell you, that strategy isn’t a pipe dream… It’s the same flagship strategy Chris Pulver just released an urgent briefing on! And your friends at Prosperity Pub have secured the video just for you. And with the very next trade dropping THIS WEEK you couldn't have better timing! While we cannot promise future returns or against losses, you have to…
See More Headlines

DTIL Stock Analysis - Frequently Asked Questions

Precision BioSciences' stock was trading at $10.95 at the start of the year. Since then, DTIL stock has decreased by 23.6% and is now trading at $8.37.
View the best growth stocks for 2024 here
.

Precision BioSciences, Inc. (NASDAQ:DTIL) posted its quarterly earnings data on Thursday, August, 1st. The company reported $3.46 EPS for the quarter, topping the consensus estimate of ($0.77) by $4.23. The firm had revenue of $49.90 million for the quarter, compared to analyst estimates of $8.50 million. Precision BioSciences had a negative trailing twelve-month return on equity of 23.69% and a net margin of 11.48%.

Precision BioSciences's stock reverse split on the morning of Wednesday, February 14th 2024. The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Precision BioSciences (DTIL) raised $126 million in an initial public offering (IPO) on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO.

Precision BioSciences' top institutional investors include Moloney Securities Asset Management LLC (0.44%). Insiders that own company stock include Derek Jantz, J Jefferson Smith, John Alexander Kelly, Dario Scimeca and Alan List.
View institutional ownership trends
.

Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Precision BioSciences investors own include Editas Medicine (EDIT), Luminar Technologies (LAZR), CRISPR Therapeutics (CRSP), Palantir Technologies (PLTR), Enovix (ENVX), Nokia Oyj (NOK) and Ginkgo Bioworks (DNA).

Company Calendar

Last Earnings
8/01/2024
Today
11/12/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/26/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DTIL
Fax
N/A
Employees
200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$39.50
High Stock Price Target
$60.00
Low Stock Price Target
$19.00
Potential Upside/Downside
+371.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-61,320,000.00
Pretax Margin
15.28%

Debt

Sales & Book Value

Annual Sales
$48.73 million
Book Value
$8.46 per share

Miscellaneous

Free Float
7,364,000
Market Cap
$64.20 million
Optionable
No Data
Beta
1.71
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:DTIL) was last updated on 11/12/2024 by MarketBeat.com Staff
From Our Partners